An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release
Miguel B. Gaspar(Portuguese Sea and Atmosphere Institute), Mark Cobbold(Kala Pharmaceuticals (United States))
Cited by 3
Related Papers
Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
|Cancer Immunology Research|2017|141